These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 17339891)

  • 21. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.
    Etienne MC; Chazal M; Laurent-Puig P; Magné N; Rosty C; Formento JL; Francoual M; Formento P; Renée N; Chamorey E; Bourgeon A; Seitz JF; Delpero JR; Letoublon C; Pezet D; Milano G
    J Clin Oncol; 2002 Jun; 20(12):2832-43. PubMed ID: 12065560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
    Amatori F; Di Paolo A; Del Tacca M; Fontanini G; Vannozzi F; Boldrini L; Bocci G; Lastella M; Danesi R
    Pharmacogenet Genomics; 2006 Nov; 16(11):809-16. PubMed ID: 17047489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.
    Wang W; Marsh S; Cassidy J; McLeod HL
    Cancer Res; 2001 Jul; 61(14):5505-10. PubMed ID: 11454699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability.
    Kitchens ME; Forsthoefel AM; Barbour KW; Spencer HT; Berger FG
    Mol Pharmacol; 1999 Nov; 56(5):1063-70. PubMed ID: 10531414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
    van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
    Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen.
    Grem JL; Danenberg KD; Behan K; Parr A; Young L; Danenberg PV; Nguyen D; Drake J; Monks A; Allegra CJ
    Clin Cancer Res; 2001 Apr; 7(4):999-1009. PubMed ID: 11309351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
    Van Triest B; Pinedo HM; Giaccone G; Peters GJ
    Ann Oncol; 2000 Apr; 11(4):385-91. PubMed ID: 10847455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thymidylate synthase pharmacogenetics in colorectal cancer.
    Marsh S; McLeod HL
    Clin Colorectal Cancer; 2001 Nov; 1(3):175-8; discussion 179-81. PubMed ID: 12450432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase.
    Kuo WT; Tu DG; Chiu LY; Sheu GT; Wu MF
    Oncol Rep; 2017 Nov; 38(5):2787-2795. PubMed ID: 28901493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].
    Ishida H; Yamada H; Shirakawa K; Nakada H; Ohsawa T; Takeuchi I; Okada N; Yokoyama M; Inokuma S; Suzuki T; Odaka A; Hoshino T; Murata N; Hashimoto D; Itoyama S; Mori T; Matsumoto Y; Miura T
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1621-6. PubMed ID: 14619479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-resistant variants of Escherichia coli thymidylate synthase: effects of substitutions at Pro-254.
    Fantz C; Shaw D; Jennings W; Forsthoefel A; Kitchens M; Phan J; Minor W; Lebioda L; Berger FG; Spencer HT
    Mol Pharmacol; 2000 Feb; 57(2):359-66. PubMed ID: 10648646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer.
    Xi Y; Nakajima G; Schmitz JC; Chu E; Ju J
    BMC Genomics; 2006 Apr; 7():68. PubMed ID: 16584549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The means to an end of tumor cell resistance to chemotherapeutic drugs targeting thymidylate synthase: shoot the messenger.
    Berg RW; Ferguso PJ; DeMoor JM; Vincen MD; Koropatnick J
    Curr Drug Targets; 2002 Aug; 3(4):297-309. PubMed ID: 12102601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
    Noordhuis P; Laan AC; van de Born K; Losekoot N; Kathmann I; Peters GJ
    Biochem Pharmacol; 2008 Jul; 76(1):53-61. PubMed ID: 18508032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
    Nita ME; Tominaga O; Nagawa H; Tsuruo T; Muto T
    Hepatogastroenterology; 1998; 45(24):2117-22. PubMed ID: 9951876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer.
    Merkelbach-Bruse S; Hans V; Mathiak M; Sanguedolce R; Alessandro R; Rüschoff J; Büttner R; Houshdaran F; Gullotti L
    Oncol Rep; 2004 Apr; 11(4):839-43. PubMed ID: 15010882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies.
    Longley DB; Ferguson PR; Boyer J; Latif T; Lynch M; Maxwell P; Harkin DP; Johnston PG
    Clin Cancer Res; 2001 Nov; 7(11):3533-9. PubMed ID: 11705873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients.
    Paradiso A; Simone G; Petroni S; Leone B; Vallejo C; Lacava J; Romero A; Machiavelli M; De Lena M; Allegra CJ; Johnston PG
    Br J Cancer; 2000 Feb; 82(3):560-7. PubMed ID: 10682666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel approach to thymidylate synthase as a target for cancer chemotherapy.
    Li Q; Boyer C; Lee JY; Shepard HM
    Mol Pharmacol; 2001 Mar; 59(3):446-52. PubMed ID: 11179438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies.
    Ricciardiello L; Ceccarelli C; Angiolini G; Pariali M; Chieco P; Paterini P; Biasco G; Martinelli GN; Roda E; Bazzoli F
    Clin Cancer Res; 2005 Jun; 11(11):4234-40. PubMed ID: 15930362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.